Depression and Anxiety Trial, Recruiting NCT06412315 Sponsor: University of Oxford Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT06412315
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their consent to take part in the research.
  • People who are sufficiently fluent in English to understand and complete the study tasks.

Who may not be able to join:

  • People who have metal objects inside their body (such as metal implants, vessel clips, or shrapnel) or implanted devices that could be harmed by a strong magnet (such as a pacemaker).
  • People who have any other reason they cannot safely have an MRI scan, as identified through a safety screening process.
  • People who have a history of, or are currently experiencing, a significant mental health condition (such as major depression).
  • People who have ever been diagnosed with a significant personality disorder (such as borderline personality disorder), based on their own report.
  • People diagnosed with ADHD or autism spectrum disorder where the condition significantly affects daily life, requires medication, or in the opinion of the study doctor could affect the reliability of the study results.
  • People who are currently taking, or have taken within the last 3 months, any medications that affect the mind or mood (this would need further discussion with the research team).
  • People who are currently using, or have used within the last 3 months, any medication that could interact with the study drug citalopram or affect the reliability of the study results.
  • People who have a known reason they cannot take citalopram, including: a past allergic reaction to citalopram or similar medicines, a heart or cardiovascular condition, glaucoma, type 1 or type 2 diabetes, epilepsy, a previous diagnosis of angle-closure glaucoma, or currently taking any other medication that is known to interact with citalopram (such as those linked to a heart rhythm problem called prolonged QT-interval).
  • People who have any current or past medical conditions that the study doctor believes could affect their safety or the reliability of the study results, including epilepsy or seizures, brain injury, liver or kidney disease, diabetes, severe digestive problems, brain tumours, or other neurological conditions.
  • People whose urine drug screen, pulse, or blood pressure readings are outside a clinically acceptable range (though the study doctor may still consider some individuals on a case-by-case basis if the finding is unlikely to add risk or affect the study).
  • People who currently have an alcohol or substance misuse disorder.
  • People whose Body Mass Index (a measure of body weight relative to height) is below 18 or above 30.
  • People who are pregnant, planning to become pregnant, or currently breastfeeding.
  • People who have previously taken part in a study using similar computer tasks to those in this study (such as an MRI faces task or emotional test battery).
  • People who have taken part in a study involving a mind- or mood-affecting medication or brain stimulation within the last three months.
  • People who have used recreational drugs (such as cannabis, cocaine, or amphetamines) within the last three months.
  • People who smoke more than 5 cigarettes per day, or who vape a comparable amount (more than 0.5ml, roughly a quarter of a 2ml vape, per day).
  • People who typically drink more than 6 caffeinated drinks per day (such as tea, coffee, cola, or energy drinks).
  • People who the study investigator believes are unlikely to follow the study procedures, or who are considered unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +441865 618338

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 February 2025
Est. completion
31 October 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Neural measures: fMRI BOLD univariate analysis; Neural measures: fMRI BOLD multivariate analysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov